

# Viktor Soukup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150078/publications.pdf>

Version: 2024-02-01

42  
papers

5,389  
citations

304602

22  
h-index

289141

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4976  
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461.	0.9	1,594
2	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta/T1 and T1/T2) 2016. European Urology, 2016, 68, 101-107.	0.9	936
3	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and T1/T2) 2016. European Urology, 2016, 68, 101-107.	0.9	559
4	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	0.9	532
5	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology, 2017, 72, 801-813.	0.9	205
6	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
7	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	0.9	190
8	Narrow Band Imaging Cystoscopy Improves the Detection of Non-muscle-invasive Bladder Cancer. Urology, 2010, 76, 658-663.	0.5	139
9	5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU International, 2005, 96, 798-802.	1.3	132
10	Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature. European Urology, 2012, 62, 290-302.	0.9	121
11	The impact of transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU International, 2016, 118, 44-52.	1.3	110
12	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	1.3	77
13	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. European Urology Focus, 2020, 6, 479-489.	1.6	72
14	Urinary Cytology and Quantitative BTA and UBC Tests in Surveillance of Patients with pTa/T1 Bladder Urothelial Carcinoma. Urology, 2008, 71, 718-722.	0.5	55
15	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	2.6	54
16	MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma, 2016, 63, 799-808.	0.7	52
17	Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. Urologia Internationalis, 2016, 96, 25-31.	0.6	37
18	Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. Urologia Internationalis, 2015, 95, 56-64.	0.6	35

#	ARTICLE	IF	CITATIONS
19	Does the Expression of Fascin-1 and Tumor Subclassification Help to Assess the Risk of Recurrence and Progression in T1 Urothelial Urinary Bladder Carcinoma?. <i>Urologia Internationalis</i> , 2008, 80, 413-418.	0.6	29
20	Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. <i>Neoplasma</i> , 2013, 60, 295-301.	0.7	29
21	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	0.8	27
22	The Prognostic Value of T1 Bladder Cancer Substaging: A Single Institution Retrospective Study. <i>Urologia Internationalis</i> , 2014, 92, 150-156.	0.6	25
23	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. <i>European Urology</i> , 2022, 82, 182-192.	0.9	25
24	Anaplastic variant of spermatocytic seminoma. <i>Pathology Research and Practice</i> , 2007, 203, 621-624.	1.0	22
25	Prevention of bladder cancer incidence and recurrence. <i>Current Opinion in Urology</i> , 2018, 28, 80-87.	0.9	18
26	Pigmented microcystic chromophobe renal cell carcinoma. <i>Pathology Research and Practice</i> , 2007, 203, 593-597.	1.0	14
27	Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. <i>Urology</i> , 2006, 67, 756-761.	0.5	13
28	Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of Prostate Cancer. <i>Urologia Internationalis</i> , 2015, 95, 429-435.	0.6	13
29	Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. <i>Cancer Letters</i> , 2006, 242, 68-76.	3.2	12
30	Prognostic Importance of Vitamins A, E and Retinol-binding Protein 4 in Renal Cell Carcinoma Patients. <i>Anticancer Research</i> , 2017, 37, 3801-3806.	0.5	10
31	Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells. <i>Anticancer Research</i> , 2016, 36, 2019-26.	0.5	10
32	Primary Large Cell Neuroendocrine Carcinoma of the Kidney. <i>Pathology and Oncology Research</i> , 2010, 16, 139-142.	0.9	9
33	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528.	1.6	8
34	Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A. <i>Anticancer Research</i> , 2018, 38, 239-246.	0.5	8
35	Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 97-100.	0.8	6
36	Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 381-390.	1.6	5

#	ARTICLE	IF	CITATIONS
37	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	1.6	4
38	PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	2
39	1697 PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
40	The safety of neoadjuvant hormonal treatment in infants with cryptorchidism. <i>Journal of Pediatric Urology</i> , 2022, , .	0.6	1
41	MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
42	PD48-07 RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT. <i>Journal of Urology</i> , 2017, 197, .	0.2	0